Replies to post #133391 on Biotech Values

[DewDiligence]

White lie from ONTY’s CEO:

http://www.reuters.com/article/2012/01/11/us-healthcare-oncothyreon-idUSTRE80A24F20120111

“We would be perfectly content if the decision is to continue the [Stimuvax] trial to its end,” Kirkman said.

In truth, he will be disappointed if this should happen. Failure of Stimuvax to hit the success threshold in the second interim analysis would further narrow the window for the best-case scenario in which Stimuvax shows extraordinarily strong efficacy.

p.s. I have a 5% ONTY position in the SI Charity Contest.

[DewDiligence]

Luke Timmerman writes on ONTY’s ‘Son of Stimuvax’, ONT-10:

http://www.xconomy.com/seattle/2012/04/10/oncothyreon-marches-on-with-son-of-stimuvax-cancer-vaccine